Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO.Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager

Calliditas to present at JP Morgan Healthcare Conference

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California. Calliditas will present an update on the company at 7:30 am PT on Tuesday 9th January. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com The information was sent for publication, through the agency of the

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain · Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing · Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMDLund, January 6, 2024. Hansa Biopharma today announced a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financials for the fourth quarter and full year 2023. Søren Tulstrup,

BAKKAFROST: Q4 2023 Trading Update

In Q4 2023 the harvest volumes for Bakkafrost’s operation in the Faroe Islands and Scotland were: Faroe Islands: 16.0 thousand tonnes · Farming North   10.5 thousand tonnes · Farming West     3.9 thousand tonnes · Farming South    1.7 thousand tonnes Scotland: 1.1 thousand tonnes · North   1.0 thousand tonnes       · South   0.0 thousand tonnes The total harvest for 2023 in the Faroe Islands was 52.4 thousand tonnes and in Scotland the total harvest in 2023 was 20.6 thousand tonnes. The total harvest from the Bakkafrost Group in 2023 was 73.0 thousand tonnes.

Tele Radio opens its 26th subsidiary in Denmark

Gothenburg, January 6th, 2024 Further increasing its worldwide network in the field of wireless, industrial remote controls, the Tele Radio Group announces the opening of a new subsidiary in Denmark. Tele Radio Denmark ApS, based in Svenstrup near Aalborg, will be the 26th subsidiary and has opened its doors officially on December 1st, 2023.Helene Kyo Johansen will lead Tele Radio Denmark as its General Manager and Sales Manager. Helene has a successful 13-year trajectory as product manager in Tele Radio’s sister company Åkerströms as well as 20 years of sales experience throughout her

New COVID vaccine induces good antibody response to mutated viral variants

Researchers at Karolinska Institutet and Danderyd Hospital in Sweden have followed recipients of the new updated COVID-19 vaccine and analysed the antibody response to different SARS-CoV-2 variants. The results published in The Lancet Infectious Diseases show a surprisingly strong response to the now dominant and highly mutated Omicron variants.The ongoing COMMUNITY study , which was launched in the spring of 2020 with the regular testing of 2,149 members of the Danderyd Hospital staff, has recently published the results of this autumn’s leg of the study.

Nordea Bank Abp: Repurchase of own shares on 05.01.2024

Nordea Bank AbpStock exchange release – Changes in company’s own shares05.01.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 05.01.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |59,382 |11.62 |690,292.00

Prostatype Genomics announces preliminary outcome of the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Transaction in Own Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 05 January 2024 REDDE NORTHGATE PLC (“Redde Northgate” or the “Group” or the “Company”)   Transaction in Own Shares   Redde Northgate plc (LSE:REDD) announces that on 05 January 2024 it purchased the following number of its own shares to be held in treasury:   Class of shares :  Ordinary shares of 50p (“shares”)

Post-Stabilisation Notice

DZ Bank AG: Post-Stabilisation Notice Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. DZ BANK AG (contact: Ralph Ockert; telephone: +49 69 7447 7051) herebygives notice that no stabilisation (within the meaning of Article 3.2 (d) of the Market Abuse Regulation (EU Regulation 596/2014) was undertaken by the Stabilising Managers named below in relation to the offer of the following securities. The security to be stabilised:    Issuer:                           German State of North

Fodelia Oyj: Share Repurchase 5.1.2024

Fodelia Oyj Announcement  5.1.2024 Fodelia Oyj: Share Repurchase 5.1.2024 In the Helsinki Stock Exchange Trade date           5.1.2024Bourse trade         BuyShare                  FODELIAAmount             1 500 SharesAverage price/ share    5,7429 EURTotal cost            8 614,35 EUR Fodelia Oyj now holds a total of 20 281 sharesincluding the shares repurchased on 5.1.2024 On behalf of Fodelia Oyj Nordea Bank Oyj Janne Sarvikivi

#24-5 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

DNB Bank ASA – status of share buy-back programme after week 1 2024

On 22 December 2023, DNB Bank ASA (“DNB”) announced that the company has decided to initiate a share buy-back programme comprising up to 0.75 percent of the company’s own shares, which represents a total of 11 569 599 shares. Up to 7 635 935 shares will be purchased on trading venues by 8 March 2024, and a proposal to cancel the shares will be made at the Annual General Meeting in 2024. At the same meeting it will also be proposed to redeem the remaining shares – up to 3 933 664 shares – from the Norwegian Government, represented by the Ministry of Trade, Industry and Fisheries (“NFD”),

Bonheur ASA completed tap issue

Today, Bonheur ASA has successfully completed a NOK 150 million tap issue in its outstanding 5-year senior unsecured green bond issue due September 15, 2028 with ISIN NO 0013014688(the "Bonds"). Total outstanding amount under the Bonds following the tap issue is NOK 750  million. The tap issue was priced at 101% of par equivalent to spread to maturity of 2,74%. The tap issue was initiated by reversed inquiries. Net proceeds from the tap issue will be used to finance green projects as further defined by the Bonheur’s green finance framework. Pareto Securities acted as sole arranger for the

Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act

Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act Musti Group plc                         Stock Exchange Release                                         5 January 2024 at 18.00 Musti Group plc (the “Company”) has on 5 January 2024 received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act from The Goldman Sachs Group, Inc. (”GS”), according to which Goldman Sachs International’s holding of the shares and votes of the Company increased above the threshold of 5 percent on 3

Ellos Group cancels written procedure for its Senior Secured Bonds

Press release, Borås, 5 January 2024 On 15 December 2023, Ellos Group AB (publ) (“Ellos Group” or the “Company”) instructed Nordic Trustee & Agency AB (publ) (the “Agent”) as agent under the Company’s outstanding SEK 1,500,000,000 Senior Secured Callable Floating Rate Bonds with ISIN SE0012827996 (the “Bonds”) to initiate a written procedure in relation to the Bonds to propose that the holders of the Bonds (the “Bondholders”) vote in favour of certain amendments of the terms and conditions of the Bonds. The Company has today withdrawn its proposal and requested that the Agent cancels the

EQT Infrastructure to partner with EdgeConneX to develop data centers for global hyperscale customers

· This investment will enable expansion into new markets around the world to fulfill customers’ global data center capacity requirements and become their provider of choice · This new partnership will build out hundreds of megawatts of new data center capacity to support future cloud, AI and other critical digital infrastructure requirementsEQT is pleased to announce that the EQT Infrastructure VI fund (“EQT Infrastructure”) has agreed to partner with EdgeConneX to build and operate high-powered and purpose-built data centers for hyperscale customers around the world, expanding into new

Resolutions of Annual General Meeting in SameSystem A/S.

Company Announcement No. 1-2024Copenhagen, 5 January 2024 SameSystem A/S will delist from Nasdaq First North Growth Market Denmark. The last day of trading shares in SameSystem A/S on Nasdaq First North Growth Market Denmark will be Thursday, 18 January 2024. The Annual General Meeting of SameSystem A/S took place on January 5, 2024, at SameSystem A/S, Rentemestervej 2A, 2400 København NV, in accordance with the agenda. The board of directors elected Søren Brinkmann, attorney-at-law, as chairman of the meeting. Leif Vestergaard, Chairman of the Board of SameSystem, accounted

Cereno Scientific releases Insights video season 2 episode 7 with Prof. Benza

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that episode 7 of season 2 in the Insights Video Series has been released. The video highlights the rationale and design of the Phase 2 clinical trial in PAH with drug candidate CS1, a controlled-release formulation of valproic acid. It further provides commentary on the recently published research article in the medical journal Pulmonary Circulation about the design of the Phase II study with CS1. Participating in the video is Raymond L. Benza,

Zwipe AS announces management change

OSLO, NORWAY – 5 January 2024 – Zwipe has appointed Hugo Petit as interim CFO with Zwipe’s current CFO and Head of IR, Danielle Glenn, deciding to leave the company to join a capital markets advisory and consulting firm Ms. Glenn has been responsible for Zwipe’s capital markets activities, including the two rights issues in 2023. She has also been instrumental in designing Zwipe’s overall strategic, operating, and investment plans and in restructuring the company to maximize financial flexibility and liquidity. Mr. Petit will join Zwipe as soon as possible, bringing over 20 years of

Pihlajalinna Plc: Managers’ transactions

Pihlajalinna Plc      Managers’ transactions     5 January 2024 at 3:00 p.m. Pihlajalinna Plc: Managers’ transactions Pihlajalinna Plc has received the following notification on 3 January 2024: Person subject to the notification requirementName: Tuomas HyyryläinenPosition: Chief Executive Officer Issuer: Pihlajalinna OyjLEI: 74370058MTRLEDOCHV67 Notification type: INITIAL NOTIFICATIONReference number: 48530/4/4____________________________________________Transaction date: 2024-01-02Outside a trading venueInstrument type: SHAREISIN: FI4000092556Nature of

There are no items matching the current filter
There are no more items matching the current filter
Back to top